Reports Monitor Global Biosimilar Market Estimates And Forecast

Bio-similar Market is expected to grow at a CAGR of 27.1% from 2017 to 2025, majorly due to the increasing patent expiration of the blockbuster biologics The " Global Biosimilar market, By Recombinant Products (Non-Glycosylated Proteins, Glycosylated Proteins, peptides and others) By Application (Oncology, Blood Disorders, Chronic and Auto-immune Disease, infectious diseases and others) opportunities and forecast 2017-2025" report has been added to Reports Monitor's database. The study for Biosimilar Market will provide market size, estimates and forecast based on the following years : Historic data: 2015 Base Year Estimate: 2016 Forecast: 2017 to 2025 Biosimilars are the copied version of biologics that have undergone patent expiration. The major factors that are driving the growth of the market includes increasing demand for these drugs due to rising geriatric population, their cost-effectiveness, strategic collaborations ensuring enhanced throughput and clinical trial activities for these drugs, and increasing support from the government and initiatives to develop and promote these drugs. Get a Free Sample of this Report @ https://www.reportsmonitor.com/request- sample/?post=581161 Europe has around 27 biosimilar drugs available, US has been slower to hold on this trend. Recently, the growth is accelerating due to patent expiration of popular biologics. Also, it is expected that the rising acceptance of these drugs by governments and physicians, and the growth of real-world evidence will help build patient confidence and trust with regards to the efficacy and safety of these products. This, in turn will drive growth in the market. Furthermore, as the price of these drugs is 30 to 50 per cent lower than the originals, there exist huge potential healthcare cost savings, which will also drive the market for these copied drugs. Currently, there are more of these drugs in progress across the Asia-Pacific than anywhere else, leading to numerous great opportunities. Producers of these drugs in Asian countries share various benefits over their competitors in US and EU markets.